C09. Safety Reporting and Clinical Incidents - What to Report and Why
Tracks
Clinical Research
Friday, June 14, 2024 |
1:30 PM - 2:30 PM |
Parkside 2 |
Chair & Speakers
Radhika Butala
Manager, Clinical Trials & Research Unit
Northshore Private Hospital, Part of Ramsay Healthcare
Chair: Safety Reporting and Clinical Incidents - What to Report and Why
Abstract
The NHMRC Safety Monitoring and Reporting Guideline (2016) is complex and there are reported inconsistencies in its interpretation and variation in its application. This may partly be due to a lack of clarity in the document and partly due to resistance in some organisations to following the Guideline. This interactive session aims to clarify the Safety Reporting Guidelines by addressing common misconceptions in its interpretation.
Action 1.11 of the National Clinical Trials Governance Framework refers to the requirement for healthcare organisations to maintain systems for the appropriate identification and management of incidents related to the provision of clinical trial services. The session will address the reported confusion about which trial events meet the definition of a clinical incident. It will introduce the ARCS White Paper: Identifying Incidents Relating to Clinical Trial Service Provision. The document aims to clarify and standardise the reporting of incidents that arise from clinical trials.
Action 1.11 of the National Clinical Trials Governance Framework refers to the requirement for healthcare organisations to maintain systems for the appropriate identification and management of incidents related to the provision of clinical trial services. The session will address the reported confusion about which trial events meet the definition of a clinical incident. It will introduce the ARCS White Paper: Identifying Incidents Relating to Clinical Trial Service Provision. The document aims to clarify and standardise the reporting of incidents that arise from clinical trials.
Biography
Radhika is a passionate Clinical Researcher and Site Advocate with over 17 years of experience and expertise from Trial Coordination to Trial Unit establishment. She has diverse clinical trial expertise in interventional and device studies spread across multiple therapeutic areas. She has operational and managerial experience in the public, private, commercial and academic sectors within the clinical research industry and the Australian Healthcare sector. She is passionate about collaborating, educating and championing young people to seek careers in clinical research. In her current role as Manager of Clinical Trials & Research Unit (CTRU) at North Shore Private Hospital, she is establishing a clinical research unit.
Tanya Symons
Safety Reporting and Clinical Incidents - What to Report and Why
Abstract
The NHMRC Safety Monitoring and Reporting Guideline (2016) is complex and there are reported inconsistencies in its interpretation and variation in its application. This may partly be due to a lack of clarity in the document and partly due to resistance in some organisations to following the Guideline. This interactive session aims to clarify the Safety Reporting Guidelines by addressing common misconceptions in its interpretation.
Action 1.11 of the National Clinical Trials Governance Framework refers to the requirement for healthcare organisations to maintain systems for the appropriate identification and management of incidents related to the provision of clinical trial services. The session will address the reported confusion about which trial events meet the definition of a clinical incident. It will introduce the ARCS White Paper: Identifying Incidents Relating to Clinical Trial Service Provision. The document aims to clarify and standardise the reporting of incidents that arise from clinical trials.
Action 1.11 of the National Clinical Trials Governance Framework refers to the requirement for healthcare organisations to maintain systems for the appropriate identification and management of incidents related to the provision of clinical trial services. The session will address the reported confusion about which trial events meet the definition of a clinical incident. It will introduce the ARCS White Paper: Identifying Incidents Relating to Clinical Trial Service Provision. The document aims to clarify and standardise the reporting of incidents that arise from clinical trials.
Biography
Tanya has worked on Commonwealth and State government projects and for the UK National Institute of Health and Care Research (NIHR). She has authored or co-authored several national guidelines and resources, including the NIHR Clinical Trials Toolkit, the Australian Clinical Trials Handbook, the NHMRC Safety Monitoring and Reporting Guidelines and Serious Breach Guidelines, and the ACTA/CTIQ Consumer Involvement and Engagement Toolkit. Tanya has provided clinical trial and GCP training to over 80,000 people.
Dianne Biermann
Research Quality Manager
Cabrini Health
Safety Reporting and Clinical Incidents - What to Report and Why
Biography
Dianne Biermann is the Research Quality Manager at Cabrini Health where she is responsible for the implementation of the National Clinical Trials Governance Framework. Dianne has over 15 years experience in research governance, health policy, and advocacy. She has a degree in Science and Postgraduate Diploma in Public Health. Dianne brings a valuable on the ground perspective of compliance with regulatory guidelines.
James Cokayne
Nsw Office For Health And Medical Research
Safety Reporting and Clinical Incidents - What to Report and Why
Biography
James Cokayne leads the Research Ethics and Governance Unit and the REGIS team at the NSW Office for Health and Medical Research (OHMR). With a medico-legal background he has worked extensively within the NSW Public Health System.
He has also had significant involvement in the private health, university and non-government sectors.
At OHMR, he is the NSW delegate on the NMA Interjurisdictional Working Group, part of the NSW delegation at the InterGovernmental Policy Reform Group (IGPRG) and before that on the Clinical Trials Project Reference Group (CTPRG) and has recently stepped down after 10 years as Chair of the SEBS (now NaCTA) Panel. He is the NSW Health advisor for research policy-related queries for Ethics, Governance, Insurance and Indemnity in Clinical Trials, Guardianship, Human Tissue and the Early Phase Clinical Trial HREC Framework. He is also the primary contact for Animal Ethics issues within NSW Health.
James has bachelor’s degrees in Law (LLB)(Hons) and Health Information Management (HIM) and a master’s degree in Health Law (MHL).